Anavex Life Sciences Corp.
AVXL
$9.42
-$0.03-0.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.15M | 2.91M | 2.86M | 2.79M | 2.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.18M | 13.64M | 14.20M | 12.05M | 10.79M |
| Operating Income | -13.18M | -13.64M | -14.20M | -12.05M | -10.79M |
| Income Before Tax | -12.11M | -11.74M | -12.28M | -10.44M | -8.62M |
| Income Tax Expenses | -- | -124.00K | -67.00K | 105.00K | -- |
| Earnings from Continuing Operations | -12.11M | -11.62M | -12.21M | -10.55M | -8.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.11M | -11.62M | -12.21M | -10.55M | -8.62M |
| EBIT | -13.18M | -13.64M | -14.20M | -12.05M | -10.79M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.14 | -0.14 | -0.14 | -0.13 | -0.11 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.09 | -0.08 | -0.07 |
| EPS Diluted | -0.14 | -0.14 | -0.14 | -0.13 | -0.11 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.09 | -0.08 | -0.07 |
| Average Basic Shares Outstanding | 84.81M | 84.80M | 84.54M | 82.46M | 82.08M |
| Average Diluted Shares Outstanding | 84.81M | 84.80M | 84.54M | 82.46M | 82.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |